Want to see TTRX full AI Analyst Report?
TTRX Stock Chart & Stats
$2.74
--
Market closed
$2.74
--
Day’s Range― - ―
52-Week Range$2.57 - $26.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.86M
Market Cap
$285.07M
Enterprise Value$213.29
Total Cash (Recent Filing)$10.29M
Total Debt (Recent Filing)$6.12M
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding29,788,040
10 Day Avg. Volume2,856,380
30 Day Avg. Volume2,856,380
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)11.55
Price to Sales (P/S)0.00
P/FCF Ratio-19.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside483.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GX-03 Clinical ProgressInterim Phase 2 activity across a broader atopic-dermatitis population, rapid separation and no treatment-related serious adverse events support GX-03’s clinical differentiation. If sustained in the full study, this could widen its addressable market and improve approval and partnering prospects.
Platform And PipelineGX-03 combines localized, non-steroidal cytokine inhibition with a PermaFusion delivery platform, while the pipeline includes additional dermatology indications and out-licensed products. This creates multiple development and milestone pathways beyond a single trial.
Strengthened Balance SheetThe sharp increase in assets and return to positive equity, combined with very low debt, provide a stronger financial base for clinical execution. This reduces immediate leverage risk and gives management more flexibility while advancing programs toward potential revenue.
Bears Say
No Commercial RevenuePersistent absence of revenue means the business has not yet demonstrated commercial validation or self-funded growth. Rising operating losses, including materially weaker 2025 EBIT, leave results dependent on clinical success and eventual regulatory approval.
Accelerating Cash BurnThe widening operating and free-cash-flow deficits increase the resources required to complete trials and sustain the company. Continued burn can shorten the financing runway and raise execution risk before GX-03 or other products generate meaningful cash inflows.
Financing DependenceThe private placement adds useful funding, but its modest size relative to ongoing development needs also highlights reliance on external capital. Repeated equity financing may dilute holders and could constrain trial scope or strategic flexibility if markets are unreceptive.
Turn Therapeutics Inc News
TTRX FAQ
What was Turn Therapeutics Inc’s price range in the past 12 months?
Turn Therapeutics Inc lowest stock price was $2.57 and its highest was $26.50 in the past 12 months.
What is Turn Therapeutics Inc’s market cap?
Turn Therapeutics Inc’s market cap is $285.07M.
When is Turn Therapeutics Inc’s upcoming earnings report date?
Turn Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 86 days.
How were Turn Therapeutics Inc’s earnings last quarter?
Turn Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.18.
Is Turn Therapeutics Inc overvalued?
According to Wall Street analysts Turn Therapeutics Inc’s price is currently Undervalued.
Does Turn Therapeutics Inc pay dividends?
Turn Therapeutics Inc does not currently pay dividends.
What is Turn Therapeutics Inc’s EPS estimate?
Turn Therapeutics Inc’s EPS estimate is -0.09.
How many shares outstanding does Turn Therapeutics Inc have?
Turn Therapeutics Inc has 29,788,040 shares outstanding.
What happened to Turn Therapeutics Inc’s price movement after its last earnings report?
Turn Therapeutics Inc reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -6.452%.
Which hedge fund is a major shareholder of Turn Therapeutics Inc?
Currently, no hedge funds are holding shares in TTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Turn Therapeutics Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (483.94% Upside)
$16.00 (483.94% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
240.67%
Trailing 12-Months
Company Description
Turn Therapeutics Inc
Turn Therapeutics Inc., officially known as Global Health Solutions, Inc., is a pharmaceutical enterprise dedicated to developing treatments for conditions affecting the skin, nails, and eyes. The company utilizes a proprietary drug delivery system engineered to effectively permeate skin and nail tissues. This advanced technology is integrated into their solutions for both acute and chronic wound care, specifically designed to help combat antibiotic resistance. Consequently, these products empower healthcare institutions to effectively manage a broad spectrum of dermatological challenges, encompassing everything from sudden injuries and persistent wounds to general skin ailments and specific dermatoses. Global Health Solutions, Inc. was established in 2015 and maintains its headquarters in Westlake Village, California.
TTRX Stock 12 Month Forecast
Average Price Target
$16.00
▲(483.94% Upside)
Technical Analysis
AIM ImmunoTech
―
Scinai Immunotherapeutics
―
Pulmatrix
―
Dermata Therapeutics
―
Azitra Inc
―
Ownership Overview
59.05% Insiders
0.23% Mutual Funds
0.71% Other Institutional Investors
39.91% Public Companies and
Individual Investors